Bioinformatic clonality analysis of next-generation sequencing-derived viral vector integration sites.
暂无分享,去创建一个
Christof von Kalle | Richard Gabriel | Hanno Glimm | Manfred Schmidt | Anne Arens | C. von Kalle | H. Glimm | Manfred Schmidt | R. Gabriel | C. Bartholomae | P. Aubourg | Anna Paruzynski | A. Arens | N. Cartier | Patrick Aubourg | Nathalie Cartier | Anna Paruzynski | Jens-Uwe Appelt | Cynthia C Bartholomae | Derek Gustafson | Annette Deichmann | J. Appelt | A. Deichmann | Derek Gustafson | A. Paruzynski | M. Schmidt | Richard Gabriel
[1] F. Bushman,et al. Retroviral DNA Integration: ASLV, HIV, and MLV Show Distinct Target Site Preferences , 2004, PLoS biology.
[2] Tatiana A. Tatusova,et al. NCBI Reference Sequences: current status, policy and new initiatives , 2008, Nucleic Acids Res..
[3] Sean D. Mooney,et al. Identifying viral integration sites using SeqMap 2.0 , 2011, Bioinform..
[4] Alessandro Aiuti,et al. Gene therapy for immunodeficiency due to adenosine deaminase deficiency. , 2009, The New England journal of medicine.
[5] Paul Shinn,et al. HIV-1 Integration in the Human Genome Favors Active Genes and Local Hotspots , 2002, Cell.
[6] Abdul Hakkim,et al. Restoration of NET formation by gene therapy in CGD controls aspergillosis. , 2009, Blood.
[7] Shawn M. Burgess,et al. Transcription Start Regions in the Human Genome Are Favored Targets for MLV Integration , 2003, Science.
[8] Christof von Kalle,et al. Analyzing the Number of Common Integration Sites of Viral Vectors – New Methods and Computer Programs , 2011, PloS one.
[9] A. Mortellaro,et al. Correction of ADA-SCID by Stem Cell Gene Therapy Combined with Nonmyeloablative Conditioning , 2002, Science.
[10] J. Silver,et al. Novel use of polymerase chain reaction to amplify cellular DNA adjacent to an integrated provirus , 1989, Journal of virology.
[11] W. J. Kent,et al. BLAT--the BLAST-like alignment tool. , 2002, Genome research.
[12] C. von Kalle,et al. Clonal evidence for the transduction of CD34+ cells with lymphomyeloid differentiation potential and self-renewal capacity in the SCID-X1 gene therapy trial. , 2005, Blood.
[13] F. Bushman,et al. Is normal hematopoiesis maintained solely by long-term multipotent stem cells? , 2011, Blood.
[14] G Opelz,et al. QuickMap: a public tool for large-scale gene therapy vector insertion site mapping and analysis , 2009, Gene Therapy.
[15] J. Tisdale,et al. Chicken HS4 insulators have minimal barrier function among progeny of human hematopoietic cells transduced with an HIV1-based lentiviral vector. , 2011, Molecular therapy : the journal of the American Society of Gene Therapy.
[16] Terrence S. Furey,et al. The UCSC Table Browser data retrieval tool , 2004, Nucleic Acids Res..
[17] I. Lemischka,et al. The return of clonal marking sheds new light on human hematopoietic stem cells , 2001, Nature Immunology.
[18] F. Bushman,et al. The host genomic environment of the provirus determines the abundance of HTLV-1–infected T-cell clones , 2011, Blood.
[19] Hans Martin,et al. Genomic instability and myelodysplasia with monosomy 7 consequent to EVI1 activation after gene therapy for chronic granulomatous disease , 2010, Nature Medicine.
[20] James R. Knight,et al. Genome sequencing in microfabricated high-density picolitre reactors , 2005, Nature.
[21] Manfred Schmidt,et al. Hematopoietic Stem Cell Gene Therapy with a Lentiviral Vector in X-Linked Adrenoleukodystrophy , 2009, Science.
[22] Christof von Kalle,et al. Stem-cell gene therapy for the Wiskott-Aldrich syndrome. , 2010, The New England journal of medicine.
[23] Hanno Glimm,et al. High-resolution insertion-site analysis by linear amplification–mediated PCR (LAM-PCR) , 2007, Nature Methods.
[24] Frederic D. Bushman,et al. Efficacy of gene therapy for X-linked severe combined immunodeficiency. , 2010, The New England journal of medicine.
[25] Stephan Wolf,et al. Genome-wide high-throughput integrome analyses by nrLAM-PCR and next-generation sequencing , 2010, Nature Protocols.
[26] Yang Du,et al. Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1 , 2006, Nature Medicine.
[27] Jeffrey C. Miller,et al. An unbiased genome-wide analysis of zinc-finger nuclease specificity , 2011, Nature Biotechnology.
[28] M. Lardelli,et al. A hyperactive sleeping beauty transposase enhances transgenesis in zebrafish embryos , 2010, BMC Research Notes.
[29] N. Copeland,et al. Harnessing transposons for cancer gene discovery , 2010, Nature Reviews Cancer.
[30] C. von Kalle,et al. Efficient marking of human cells with rapid but transient repopulating activity in autografted recipients. , 2005, Blood.
[31] Rafael J. Yáñez-Muñoz,et al. Lentiviral vector integration profiles differ in rodent postmitotic tissues. , 2011, Molecular therapy : the journal of the American Society of Gene Therapy.
[32] A. Fischer,et al. Sustained correction of X-linked severe combined immunodeficiency by ex vivo gene therapy. , 2002, The New England journal of medicine.
[33] C. von Kalle,et al. Real-Time Definition of Non-Randomness in the Distribution of Genomic Events , 2007, PloS one.
[34] M. Koch,et al. Distinct types of tumor-initiating cells form human colon cancer tumors and metastases. , 2011, Cell stem cell.
[35] Cameron S. Osborne,et al. LMO2-Associated Clonal T Cell Proliferation in Two Patients after Gene Therapy for SCID-X1 , 2003, Science.
[36] Christine Kinnon,et al. Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients. , 2008, The Journal of clinical investigation.
[37] Takeshi Suzuki,et al. New genes involved in cancer identified by retroviral tagging , 2002, Nature Genetics.
[38] Luca Biasco,et al. Comprehensive genomic access to vector integration in clinical gene therapy , 2009, Nature Medicine.
[39] M. Dinauer,et al. Gene therapy of chronic granulomatous disease: the engraftment dilemma. , 2011, Molecular therapy : the journal of the American Society of Gene Therapy.
[40] Jérôme Larghero,et al. Transfusion independence and HMGA2 activation after gene therapy of human β-thalassaemia , 2010, Nature.
[41] B. Wold,et al. In vivo footprinting of a muscle specific enhancer by ligation mediated PCR. , 1990, Science.
[42] C. von Kalle,et al. Retroviral gene therapy for X-linked chronic granulomatous disease: results from phase I/II trial. , 2008, Molecular therapy : the journal of the American Society of Gene Therapy.
[43] F. Bushman,et al. Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1. , 2008, The Journal of clinical investigation.
[44] C. von Kalle,et al. Hepatocyte-Targeted Expression by Integrase-Defective Lentiviral Vectors Induces Antigen-Specific Tolerance in Mice with Low Genotoxic Risk , 2011, Hepatology.
[45] Feng Chen,et al. Sequencing and Analysis of Neanderthal Genomic DNA , 2006, Science.
[46] Gianluigi Zanetti,et al. Lentiviral vector common integration sites in preclinical models and a clinical trial reflect a benign integration bias and not oncogenic selection. , 2011, Blood.
[47] Christine Kinnon,et al. Mutations in TNFRSF13B Encoding TACI Are Associated With Common Variable Immunodeficiency in Humans , 2006, Pediatrics.